Delcath Systems (DCTH) Reports Q2 Loss of $0.30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Wall St futures pause after AI rally, focus on Mideast tensions
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Delcath Reports 2015 Second Quarter Financial Results
August 5, 2015 8:00 AM EDTNEW YORK, Aug. 5, 2015 /PRNewswire/ --Â Delcath Systems, Inc. (NASDAQ: DCTH), a specialty pharmaceutical and medical device company focused on oncology with an emphasis on the treatment of primary and metastatic liver cancers, announces financial results for the three and six months ended June 30, 2015.Â
Highlights of the second quarter and recent weeks included:
Quarterly product revenue of $0.5 million, an increase of nearly 85.7% compared with the second quarter of 2014 Total operating expenses decreased by 35.1% to $4.0 million from $6.1 million in the second quarter of 2014 Enrollment opened for an... MoreDelcath Announces Acceptance of Abstracts for Presentation at the European Association of Dermato Oncology Annual Congress
August 4, 2015 8:00 AM EDTNEW YORK, Aug. 4, 2015 /PRNewswire/ -- Delcath Systems, Inc. (NASDAQ: DCTH), a specialty pharmaceutical and medical device company focused on oncology with an emphasis on the treatment of primary and metastatic liver cancers, announces that two abstracts summarizing data from studies in Europe and the U.K. of treatment with the Delcath Hepatic CHEMOSAT® Delivery System (CHEMOSAT) will be presented at the upcoming European Association of Dermato Oncology (EADO) annual congress, which will be held in Marseille, France, October 28-31, 2015.
The abstracts are:
Treating Unresectable Liver... More